Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry.

Abstract

We examined possible anticancer effects of thiazolidinediones (TZDs) in 6074 Chinese with Type 2 diabetes free of cancer at enrolment. During a median follow-up of 4.93 years, 270 patients developed cancer. Use of TZDs was associated with reduced risk of cancer in a dose-response manner in multivariable analysis.

DOI: 10.1016/j.diabres.2012.03.006

Statistics

0100200201220132014201520162017
Citations per Year

118 Citations

Semantic Scholar estimates that this publication has 118 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Yang2012UseOT, title={Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry.}, author={Xilin Yang and Wing-Yee So and Ronald C W Ma and Linda Wai-Ling Yu and Alice P. S. Kong and Heung M. Lee and Gang Xu and Risa Ozaki and Gary T C Ko and Juliana C. Chan}, journal={Diabetes research and clinical practice}, year={2012}, volume={97 1}, pages={e13-7} }